ABSTRACT
Background: Epidemiological studies and clinical trials have shown that meticulous control of blood pressure is required in patients with hypertension to ensure decreased cardiovascular morbidity and mortality. Objective: To compare the effect of Metoprolol and Telmisartan on blood pressure reduction and heart rate in patients of Stage I Hypertension. Material and Methods: This was a prospective, randomized, open, parallel study conducted at the outpatient department of Medicine. Patients of either sex with Grade I Hypertension according to JNC VII, aged between 18-60 years were enrolled and followed up every 2 weeks from baseline till 12 weeks. Patients were randomly divided into two groups to receive tablet Metoprolol 50 mg (Group A, n=30) and Telmisartan 40 mg (Group B, n=30) once a day. Response to study treatments was evaluated in terms of decrease in Blood pressure and heart rate. Results were analysed using Student’s ‘t’ test. Results: Baseline characters of both the groups were well balanced. Systolic Blood Pressure was reduced by 7.5 % from Metoprolol and 12.9% by Telmisartan and Diastolic Blood Pressure was reduced by 8.2% in group A and 13.6% in group B. Both the drugs leads to significant reductions (i.e. P <0.05) in systolic as wel as diastolic BP. Heart rate reduction was significant and was observed to be more with the Metoprolol group i.e. 15.2% reduction as compared to 9.1% reduction with Telmisartan. Conclusion: Telmisartan is a better choice than Metoprolol in Indian Population for treating Grade I hypertension as it leads to greater reduction in Blood Pressure and less effect on Heart rate.
ABSTRACT
of morbidity and mortality in underdeveloped and developing countries and places a huge burden on the society in terms of health care resources and loss of productivity. Statins are the most popular hypolipidemic drug used to treat hyperlipidemia which is generally administered daily. Objectives: The study was conducted to compare the percent change of LDL-C, TC, TG and HDL and compare the safety of Rosuvastatin in patients of dyslipidemia. Material and Methods: Sixty patients were randomly divided into two groups: once daily group and Alternate day group of rosuvastatin 10mg for six weeks. The lipid profile was compared from the baseline and at end of six weeks. Results: Baseline characters of both the groups were well balanced. LDL-C was reduced by 23.8 % in once-daily group and 26.05 % in alternate-day group, respectively. Changes were also recorded for the other lipid parameters (TC, TG, HDL). Such changes were found to be of no significant difference when compared between the two groups (p>0.05 NS) Conclusion: Alternate day therapy is as effective as the once -daily dosing with rosuvastatin in Indian population in improving the lipid parameters in dyslipidemic patients.